Bangalore, India -- (SBWIRE) -- 08/11/2017 -- Myocardial Fibrosis - Pipeline Review, H1 2017, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 68 pages "Myocardial Fibrosis - Pipeline Review, H1 2017" report covers Introduction, Report Coverage, Myocardial Fibrosis - Overview, Myocardial Fibrosis - Therapeutics Development, Pipeline Overview, Myocardial Fibrosis - Therapeutics Assessment, Myocardial Fibrosis - Companies Involved in Therapeutics Development, Myocardial Fibrosis - Drug Profiles, Product Description, Myocardial Fibrosis - Dormant Projects, Appendix. This report Covered Companies - Daewoong Pharmaceutical Co Ltd, Evotec AG, Galectin Therapeutics Inc, GTx Inc, Invivosciences Inc, Lead Discovery Center GmbH, MandalMed Inc, Merck & Co Inc, miRagen Therapeutics Inc, TRACON Pharmaceuticals Inc.

For more information Visit at: http://www.drugpipeline.net/global-markets-direct/myocardial-fibrosis-pipeline-review-h1-2017

Find all Diseases Reports at - http://www.drugpipeline.net/catalog/diseases

Related Reports;

Gaucher Disease - Pipeline Review, H1 2017 - Visit at - http://www.drugpipeline.net/global-markets-direct/gaucher-disease-pipeline-review-h1-2017

Hypertension - Pipeline Review, H1 2017 - Visit at - http://www.drugpipeline.net/global-markets-direct/hypertension-pipeline-review-h1-2017

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.